Dexcom (NSDQ:DXCM) touted data today showing that people with Type II diabetes who are using multiple daily injections of insulin can benefit from the use of continuous glucose monitoring.
Those in the 158-patient study using Dexcom’s G4 Platinum CGM system experienced significant A1C reduction and spent more time in target range compared to a control group that used a standard meter to test glucose.
Get the full story at our sister site, Drug Delivery Business News.
The post Dexcom touts continuous glucose monitoring for Type II diabetes patients appeared first on MassDevice.